High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel, Alberto Rocci, Heinz Ludwig*, Arnold Bolomsky, Simona Caltagirone, Martin Schreder, Sabine Pfeifer, Heinz Gisslinger, Niklas Zojer, Ulrich Jäger, Antonio Palumbo
*Corresponding author for this work
Research output: Journal article (peer-reviewed) › Journal article
Dive into the research topics of 'High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone'. Together they form a unique fingerprint.